# OnCo record goya (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/goya/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "goya", "NCT01287741" ;
  schema:name "GOYA"@en ;
  schema:alternateName "Obinutuzumab versus rituximab in first-line diffuse large B-cell lymphoma"@en, "GOYA trial"@en ;
  schema:description "A newer antibody against the same target as rituximab was tested in first-line treatment for the commonest aggressive lymphoma and did not work better, while causing more side effects."@en ;
  schema:url <https://onco.cc/trials/goya/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01287741>, <https://doi.org/10.1200/JCO.2017.73.3402> ;
  onco:status "negative" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "3" ;
  schema:startDate "2011-07-26" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/cell-of-origin/> ;
  onco:trials <https://onco.cc/trials/gallium/> ;
  onco:people <https://onco.cc/people/laurie-sehn/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/> .